Severe Asthma in the Era of Biologics: Continuous Challenges

Asthma is a heterogenous disease characterized by different phenotypes and endo-types. Severe asthma is a unique phenotype of the disease characterized by two major endotyping mechanisms—the high T2 process and the low T2 process. The definition of severe asthma is mainly based on the high requirements of treatment regimens. In the last 20 years, biologic agents have had a central role in targeting the previously refractory T2 high process, with many randomized controlled trials (RCTs) clearly verifying both safety and efficacy [1]. Despite their effectiveness in different aspects of disease assessment there